Salix Pharmaceuticals recently announced a new, interactive virtual reality tool “intended to provide clinicians with an experiential learning platform that explores the causes of irritable bowel syndrome, or IBS.
IBS is now the most common functional gut disorder affecting between 25 and 45 million people in the United States.
So how does the new experience work?
Through an all-in-one VR headset, healthcare providers are taken on an educational “voyage” exploring several leading theories about IBS, including the role gut microbiota may play in creating IBS symptoms for patients. It will be unveiled at Digestive Disease Week (DDW) 2017 in Chicago.
“We hope this educational program helps connect the dots between the multiple theories of what causes IBS in a uniquely memorable way for physicians,” said Tage Ramakrishna, M.D., Chief Medical Officer for Salix. “The ultimate goal is to eliminate any barriers to patient care for the undiagnosed and untreated patient population.”
To learn more, click here.